4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 81 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,958,045 | -31.8% | 2,746,335 | -3.3% | 0.02% | -28.1% |
| Q2 2023 | $51,276,601 | +58.8% | 2,838,882 | +51.2% | 0.03% | +52.4% |
| Q1 2023 | $32,285,534 | -0.9% | 1,877,425 | +28.0% | 0.02% | -8.7% |
| Q4 2022 | $32,562,787 | +206.6% | 1,466,267 | -44.4% | 0.02% | +187.5% |
| Q3 2022 | $10,621,611 | +14.0% | 2,639,462 | +97.7% | 0.01% | +33.3% |
| Q2 2022 | $9,318,000 | -63.0% | 1,335,048 | -19.8% | 0.01% | -50.0% |
| Q1 2022 | $25,175,000 | -30.4% | 1,665,411 | +1.1% | 0.01% | -20.0% |
| Q4 2021 | $36,160,000 | -11.9% | 1,647,923 | +8.3% | 0.02% | -16.7% |
| Q3 2021 | $41,032,000 | +10.7% | 1,521,103 | -1.2% | 0.02% | +12.5% |
| Q2 2021 | $37,070,000 | -26.9% | 1,539,726 | +25.4% | 0.02% | -30.4% |
| Q1 2021 | $50,690,000 | +27.0% | 1,227,397 | +20.1% | 0.02% | +21.1% |
| Q4 2020 | $39,907,000 | – | 1,021,911 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 378,288 | $16,410,000 | 6.18% |
| Aquilo Capital Management, LLC | 300,886 | $13,052,000 | 2.36% |
| BVF INC/IL | 1,031,070 | $44,728,000 | 1.68% |
| Casdin Capital, LLC | 995,354 | $43,178,000 | 1.29% |
| Ally Bridge Group (NY) LLC | 150,000 | $6,507,000 | 1.25% |
| Eagle Health Investments LP | 50,000 | $2,169,000 | 0.85% |
| Soleus Capital Management, L.P. | 86,100 | $3,735,000 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $170,827,000 | 0.51% |
| ArrowMark Colorado Holdings LLC | 1,048,189 | $45,471,000 | 0.34% |
| ACUTA CAPITAL PARTNERS, LLC | 20,000 | $868,000 | 0.31% |